VERV Verve Therapeutics Inc
Price (delayed)
$3.91
Market cap
$347.19M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.35
Enterprise value
$239.84M
Highlights
VERV's gross profit has soared by 175% year-on-year and by 33% since the previous quarter
Verve Therapeutics's revenue has soared by 175% YoY and by 33% from the previous quarter
The quick ratio has declined by 28% year-on-year and by 3.3% since the previous quarter
Verve Therapeutics's equity has decreased by 18% YoY and by 3% from the previous quarter
Key stats
What are the main financial stats of VERV
Market
Valuations
Earnings
Shares outstanding
88.8M
Market cap
$347.19M
Enterprise value
$239.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.67
Price to sales (P/S)
10.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.42
Revenue
$32.33M
Gross profit
$32.33M
Operating income
-$228.66M
Net income
-$198.71M
EBIT
-$198.36M
EBITDA
-$184.39M
Free cash flow
-$161.43M
Per share
Balance sheet
Liquidity
EPS
-$2.35
EPS diluted
-$2.35
Free cash flow per share
-$1.91
Book value per share
$5.83
Revenue per share
$0.38
TBVPS
$7.64
Total assets
$647.39M
Total liabilities
$153.99M
Debt
$69.98M
Equity
$493.4M
Working capital
$499.84M
Debt to equity
0.14
Current ratio
12.65
Quick ratio
12.41
Net debt/EBITDA
0.58
Margins
Efficiency
Dividend
EBITDA margin
-570.3%
Gross margin
100%
Net margin
-614.6%
Operating margin
-707.2%
Return on assets
-29%
Return on equity
-37.3%
Return on invested capital
-35.6%
Return on capital employed
-32.8%
Return on sales
-613.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VERV stock price
How has the Verve Therapeutics stock price performed over time
Intraday
-5.44%
1 week
-27.59%
1 month
-38.23%
1 year
-53%
YTD
-30.67%
QTD
-14.44%
Financial performance
How have Verve Therapeutics's revenue and profit performed over time
Revenue
$32.33M
Gross profit
$32.33M
Operating income
-$228.66M
Net income
-$198.71M
Gross margin
100%
Net margin
-614.6%
VERV's gross profit has soared by 175% year-on-year and by 33% since the previous quarter
Verve Therapeutics's revenue has soared by 175% YoY and by 33% from the previous quarter
VERV's net margin has surged by 64% year-on-year and by 24% since the previous quarter
The operating margin has soared by 63% YoY and by 24% from the previous quarter
Growth
What is Verve Therapeutics's growth rate over time
Valuation
What is Verve Therapeutics stock price valuation
P/E
N/A
P/B
0.67
P/S
10.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.42
Verve Therapeutics's EPS has increased by 25% YoY and by 4.5% QoQ
The P/B is 35% below the last 4 quarters average of 1.1
Verve Therapeutics's equity has decreased by 18% YoY and by 3% from the previous quarter
Verve Therapeutics's revenue has soared by 175% YoY and by 33% from the previous quarter
The price to sales (P/S) is 64% less than the last 4 quarters average of 30.1
Efficiency
How efficient is Verve Therapeutics business performance
Verve Therapeutics's return on sales has surged by 64% YoY and by 24% QoQ
VERV's ROE is down by 6% QoQ but it is up by 5% YoY
The ROA has grown by 6% YoY but it has contracted by 4.7% from the previous quarter
VERV's return on invested capital is down by 4.7% since the previous quarter
Dividends
What is VERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VERV.
Financial health
How did Verve Therapeutics financials performed over time
The quick ratio has declined by 28% year-on-year and by 3.3% since the previous quarter
The current ratio has declined by 27% year-on-year and by 3.1% since the previous quarter
VERV's debt is 86% smaller than its equity
Verve Therapeutics's equity has decreased by 18% YoY and by 3% from the previous quarter
VERV's debt to equity is up by 17% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.